LDL-Cholesterol: Standards of Treatment 2016: A German Perspective (Q30248925)

13 June 2017

LDL-Cholesterol: Standards of Treatment 2016: A German Perspective (English)

1 reference

Erratum to: LDL-Cholesterol: Standards of Treatment 2016: A German Perspective

13 June 2017

corrigendum / erratum

0 references

author

Winfried März

1

0 references

Ulf Landmesser

7

object named as

Ulf Landmesser

1 reference

13 June 2017

2

Hubert Scharnagl

1 reference

13 June 2017

6

Tanja B Grammer

1 reference

13 June 2017

Ioanna Gouni-Berthold

3

1 reference

13 June 2017

Günther Silbernagel

4

1 reference

13 June 2017

Alexander Dressel

5

1 reference

13 June 2017

Hans Dieplinger

8

1 reference

13 June 2017

Eberhard Windler

9

1 reference

13 June 2017

Ulrich Laufs

10

1 reference

13 June 2017

18 July 2016

1 reference

American journal of cardiovascular drugs

13 June 2017

1 reference

13 June 2017

16

1 reference

13 June 2017

323-336

1 reference

13 June 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s40256-016-0179-y

13 June 2017

0 references

cites work

A tale of coronary artery disease and myocardial infarction

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Amid lingering questions, FDA reprieves LDL cholesterol-lowering medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Inactivating mutations in NPC1L1 and protection from coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Beyond statins: what to expect from add-on lipid regulating therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

A systematic review and meta-analysis on the therapeutic equivalence of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

PCSK9: a key modulator of cardiovascular health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Enterovirus infection is associated with an increased risk of childhood type 1 diabetes in Taiwan: a nationwide population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Advanced method for the identification of patients with inherited hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Cystatin C versus creatinine in determining risk based on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Prevalence of myocardial infarction and coronary heart disease in adults aged 40-79 years in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-016-0179-Y

10.1007/S40256-016-0179-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

13 June 2017

0 references

1 reference